Picture loading failed.

Anti-FN extra domain B therapeutic antibody (Pre-made Bifikafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-068-1mg 1mg Inquiry
GMP-Bios-ab-068-10mg 10mg Inquiry
GMP-Bios-ab-068-100mg 100mg Inquiry
GMP-Bios-ab-068-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-FN extra domain B therapeutic antibody (Pre-made Bifikafusp biosimilar,Whole mAb Fusion)
INN Name Bifikafusp
TargetFN extra domain B
FormatWhole mAb Fusion
Species ReactivityHuman
CH1 IsotypeIgE
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Diffuse large B-cell lymphoma;[With onfekafusp] Malignant melanoma;[With onfekafusp] Basal cell cancer;[With onfekafusp] Squamous cell cancer;[With onfekafusp] Solid tumours
Conditions DiscontinuedMalignant melanoma;Renal cell carcinoma;Solid tumours;Atherosclerosis;Head and neck cancer;Pancreatic cancer
Development Techna